Alicia Gonzalez-Mourelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alicia Gonzalez-Mourelle has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Outeiriño-Fernández
Centro de Saúde de Acea Da Ama, Xerencia de Xestion Integrada de A Coruña, SERGAS Galician Health Service, A Coruña, Spain
1 shared publication - Amaia Bilbao
Osakidetza Basque Health Service, Basurto University Hospital, Research and Innovation Unit; Biosistemak Institute for Health Systems Research, Bilbao, Spain
1 shared publication Beatriz Patino Seijas
A Coruna Univ Hosp, Dept Oral & Maxillofacial Surg, As Xubias 84, E-15006 La Coruna, Spain
1 shared publicationDavid Neagu
Department of Oral and Maxillofacial Surgery, A Coruña University Hospital, A Coruña, Spain
1 shared publicationInes Vazquez Mahia
A Coruna Univ Hosp, Dept Oral & Maxillofacial Surg, As Xubias 84, E-15006 La Coruna, Spain
1 shared publicationInés Vázquez Mahía
Department of Oral and Maxillofacial Surgery, A Coruña University Hospital, A Coruña, Spain
1 shared publication
Latest Publications
- 4 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (3) , 995-1004
Diagnostic imaging modalities to detect regional nodal involvement in oral squamous cell carcinoma: a systematic review and meta-analysis
Objectives To determine the most effective diagnostic imaging modality including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography–computed tomography (PET/CT), and ultrasound (US) for the identification of regional lymph node involvement in patients with oral squamous cell carcinoma (OSCC). Methods A search was performed to identify qualified studies using PubMed, Scopus, and Web of Science electronic databases from January 2013 to December 2023. The outcome assessed was the diagnostic performance of different imaging techniques in the detection of cervical lymph node metastasis in OSCC, with lymph node yield in neck dissection specimens as the gold standard for validation. Summary estimates for diagnostic performance were sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs). Differences in sensitivities, specificities, and DOR were tested using a bivariate random effects model. Results Twelve observational studies including PET/CT, MRI, and CT alone or combined in OSCC patients were included in the meta-analysis. Data from a single study based on US were insufficient to assess the value of this imaging modality. The pooled estimates of sensitivity were 0.87 for PET/CT, 0.70 for MRI, and 0.66 for CT. The corresponding pooled specificities were 0.79, 0.79, and 0.81, respectively. The DOR was 24.85 for PET/CT, 8.60 for MRI, and 8.59 for CT. Conclusion PET/CT may be recommended in clinical practice for detecting cervical metastatic disease in OSCC patients as this technique showed the most favorable diagnostic performance as compared with MRI and CT.
- 4 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (3) , 995-1004
Diagnostic imaging modalities to detect regional nodal involvement in oral squamous cell carcinoma: a systematic review and meta-analysis
Objectives To determine the most effective diagnostic imaging modality including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography–computed tomography (PET/CT), and ultrasound (US) for the identification of regional lymph node involvement in patients with oral squamous cell carcinoma (OSCC). Methods A search was performed to identify qualified studies using PubMed, Scopus, and Web of Science electronic databases from January 2013 to December 2023. The outcome assessed was the diagnostic performance of different imaging techniques in the detection of cervical lymph node metastasis in OSCC, with lymph node yield in neck dissection specimens as the gold standard for validation. Summary estimates for diagnostic performance were sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs). Differences in sensitivities, specificities, and DOR were tested using a bivariate random effects model. Results Twelve observational studies including PET/CT, MRI, and CT alone or combined in OSCC patients were included in the meta-analysis. Data from a single study based on US were insufficient to assess the value of this imaging modality. The pooled estimates of sensitivity were 0.87 for PET/CT, 0.70 for MRI, and 0.66 for CT. The corresponding pooled specificities were 0.79, 0.79, and 0.81, respectively. The DOR was 24.85 for PET/CT, 8.60 for MRI, and 8.59 for CT. Conclusion PET/CT may be recommended in clinical practice for detecting cervical metastatic disease in OSCC patients as this technique showed the most favorable diagnostic performance as compared with MRI and CT.
- Open Access
- 1 January 2019
- Published by Medknow in National Journal of Maxillofacial Surgery
- Vol. 10 (1) , 87-90
Facial tumor as a presenting complaint in a patient with primary Sjögren's syndrome
Sjögren's syndrome is a chronic autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates of the affected glands. Dryness of the mouth and eyes results from involvement of the salivary and lacrimal glands. Up to one-half of affected individuals also develop extraglandular involvement in organs distinct from the salivary and lacrimal glands, including the joints, skin, lung, gastrointestinal tract, nervous system, and kidneys. The disease also occurs in conjunction with other autoimmune disorders, such as systemic lupus erythematosus and rheumatoid arthritis. We report a case of a 76-year-old woman who presented to our department with a swelling on the left cheek. Investigations revealed Sjögren's syndrome as the underlying cause of the facial tumor.
- 1 January 2019
- Published by Medknow in National Journal of Maxillofacial Surgery
- Vol. 10 (1) , 87-90
Open AccessFacial tumor as a presenting complaint in a patient with primary Sjögren's syndrome
Sjögren's syndrome is a chronic autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates of the affected glands. Dryness of the mouth and eyes results from involvement of the salivary and lacrimal glands. Up to one-half of affected individuals also develop extraglandular involvement in organs distinct from the salivary and lacrimal glands, including the joints, skin, lung, gastrointestinal tract, nervous system, and kidneys. The disease also occurs in conjunction with other autoimmune disorders, such as systemic lupus erythematosus and rheumatoid arthritis. We report a case of a 76-year-old woman who presented to our department with a swelling on the left cheek. Investigations revealed Sjögren's syndrome as the underlying cause of the facial tumor.
- 1 January 2018
- Vol. 21 (2) , 147-149
Osteoblastoma of the Hard Palate in a Child: A Rare Case
Benign osteoblastoma is a rare bone tumour characterised histologically by the production of woven bone spicules, which are bordered by prominent osteoblasts. It mainly affects young adults. We report a rare case of benign osteoblastoma of the maxilla in a 7-year-old boy who presented with a painful swelling on the hard palate. An incisional biopsy was interpreted as osteoblastic neoplasm most suggestive of osteoblastoma. After excision of the tumour there has been no recurrence for 2 years.
- 1 January 2018
- Vol. 21 (2) , 147-149
Osteoblastoma of the Hard Palate in a Child: A Rare Case
Benign osteoblastoma is a rare bone tumour characterised histologically by the production of woven bone spicules, which are bordered by prominent osteoblasts. It mainly affects young adults. We report a rare case of benign osteoblastoma of the maxilla in a 7-year-old boy who presented with a painful swelling on the hard palate. An incisional biopsy was interpreted as osteoblastic neoplasm most suggestive of osteoblastoma. After excision of the tumour there has been no recurrence for 2 years.